Logo

Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer

Share this

Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer

Shots:

  • The companies will develop a pipeline of products used for diagnosing and assessing the risks of thyroid cancer- leveraging Interpace’s ThyGeNEXT and ThyraMIR assays combining with Helomics’ patient-derived tumor profiling and AI platform- D-CHIP
  • Helomics to build a model utilizing Interpace’s clinical data which can be further used in identifying targets for treating indolent and aggressive thyroid cancers
  • ThyGeNEXT and ThyraMIR is a next generation sequencing and proprietary gene expression assay respectively for identifing 150+ genetic alterations associated with thyroid cancer from thyroid nodules

Click here to read full press release/ article | Ref: Interpace Diagnostics | Image: Behnace


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions